Development of a new therapeutic approach to b cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor

International Reviews of Immunology

Volumn 4, Issue 4, 1989, Pages 251-270

  Campbell, Michael J ^a   Esserman, Laura ^a   Byars, Noelene E ^b   Allison, Anthony C ^b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

Active idiotype vaccination; Chemoimmunotherapy; Humoral and cellular anti Id response; Murine B cell tumor; Primate vaccination

Indexed keywords

ANTIBODIES, ANTI IDIOTYPIC; ANTIIDIOTYPIC ANTIBODY; CANCER ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; MEMBRANE ANTIGEN; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANIMAL; B CELL LYMPHOMA; CELLULAR IMMUNITY; IMMUNOLOGY; MACACA; REVIEW;

ANIMAL; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; LYMPHOMA, B-CELL; MACACA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024773585     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830188909044782     Document Type: Article

References (36)

1. Contribution to the knowledge of sarcoma
2. Treatment of malignant tumors by repeated inoculations of erysipelos with a report of 10 cases
3. A report of recent cases of inoperable sarcomas successfully treated with mixed toxins of erysipelos and bacillus prodigiosus
4. The specific treatment of carcinoma
5. Preliminary experience in treating lymphocytic leukemia with antibody to immunoglobulin idiotypes on the cell surface
6. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody
7. A clinical trial of anti-idiotype therapy of B cell malignancy
8. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
9. Somatic mutation in human B-cell tumors
10. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants
11. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins
12. Antibodies to idiotypes of isologous immunoglobulins
13. Myeloma proteins as tumor specific transplantation antigens
14. Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens
15. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein
16. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
17. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide
18. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein
19. 1 mice
20. 1
21. 1, with different growth characteristics
22. Idiotypic vaccination as a treatment for a B cell lymphoma
23. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation
24. Myeloma-specific antibodies: Studies of their properties and their relationship to tumor immunity
25. Immunologic adjuvants: efficacy and safety considerations
26. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity
27. L domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315
28. Idiotype-specific transplantation resistance to MOPC-315: Abrogation by post-immunization thymectomy
29. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney Sarcoma virus
30. Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice
31. Indomethacin enhancement of spleen-cell responsiveness to mitogen stimulation in tumorous mice
32. Reversal of macrophage-induced spleen cell immune suppression in tumorous mice
33. Participation of the humoral immune system in the myeloma-specific transplantation resistance
34. Prevention of chemotherapy complications: Time, toxicity, pharmacokinetics, pharmacodynamic and logistic factors
35. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models
36. The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation